A previous meta-analysis of the worldwide evidence found that menopausal hormone therapy (MHT) users were at an increased risk of breast cancer. However, little information was available about the effects of different MHT types or long-term risks after MHT use had stopped. Since then, a lot of new information has become available, including results from randomised trials which generally show greater risks of breast cancer with preparations containing both oestrogen and progestagen. MHT typically begins in women around menopause and can last for several years. In Western nations, breast cancer is the most prevalent disease at these ages; According to appendix of women are diagnosed. While regulatory bodies in Europe and the United States recommend that MHT be used for the shortest amount of time necessary, breast cancer some clinical guidelines suggested prescribing it with fewer restrictions.
HTML PDFShare this article
Cancer Science & Therapy received 3968 citations as per Google Scholar report
